SCHEMBL2458079

SCHEMBL2458079

COc1ccc(/C=C/CO)cc1OC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 6/20 0.61
PTGS1 P23219 2/20 0.61
PTGS2 P35354 1/20 0.61
NFE2L2 Q16236 2/20 0.60
CYP1B1 Q16678 5/20 0.58
TUBB1 Q9H4B7 3/20 0.58
CYP1A2 P05177 2/20 0.58
TUBB4A P04350 1/20 0.58
TUBB P07437 1/20 0.58
TUBA3C P0DPH7 1/20 0.58
TUBA1B P68363 1/20 0.58
TUBA4A P68366 1/20 0.58
TUBB4B P68371 1/20 0.58
TUBB3 Q13509 1/20 0.58
TUBB2A Q13885 1/20 0.58
TUBB8 Q3ZCM7 1/20 0.58
TUBA3E Q6PEY2 1/20 0.58
TUBA1A Q71U36 1/20 0.58
TUBA1C Q9BQE3 1/20 0.58
TUBB6 Q9BUF5 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30625282 1.00 CYP1A1 (0.61) CYP1A1PTGS1PTGS2NFE2L2CYP1B1
SCHEMBL1301189 1.00 CYP1A1 (0.61) CYP1A1PTGS1PTGS2NFE2L2CYP1B1
SCHEMBL1301186 1.00 CYP1A1 (0.61) CYP1A1PTGS1PTGS2NFE2L2CYP1B1
SCHEMBL2679429 0.90 PTGS1 (0.54) CYP1A1PTGS1PTGS2NFE2L2CYP1B1
Malonic Acid SCHEMBL27751245 0.89 NFE2L2 (0.61) CYP1A1PTGS1PTGS2NFE2L2CYP1B1
SCHEMBL4686225 0.87 TUBB1 (0.56) CYP1A1PTGS1PTGS2NFE2L2CYP1B1
SCHEMBL4686223 0.87 TUBB1 (0.56) CYP1A1PTGS1PTGS2NFE2L2CYP1B1
SCHEMBL6587547 0.87 MMP9 (0.58) CYP1A1PTGS1PTGS2NFE2L2CYP1B1
SCHEMBL6587536 0.87 MMP9 (0.58) CYP1A1PTGS1PTGS2NFE2L2CYP1B1
SCHEMBL4631918 0.86 KDM4E (0.67) PTGS1TUBB1TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1071440-B1 NOVEL SYNERGISTIC COMPOSITIONS CONTAINING AROMATIC COMPOUNDS AND TERPENOIDS PRESENT IN ALPINIA GALANGA EUROVITA AS (DK) 2007-01-03 EP claimed
CN-1125651-C Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga OVEDA AS (DK) 2003-10-29 CN claimed
US-20030157204-A1 Novel synergistic compositions containing aromatic compounds and terpenoids present in Alpinia galanga ENROVITA A/S 2003-08-21 US claimed
US-6566405-B2 Drugs, cosmetics or dietary supplements; immunomodulation, antiallergens (IgE mediated allergies, e.g., asthma, rhinitis, eczema); anaphylaxis; autoimmune disorders, e.g., Crohn's disease, antiarthritic and ulcer agents; analgesics EUROVITA A/S (DK) 2003-05-20 US claimed
US-20020086906-A1 NOVEL SYNERGISTIC COMPOSITIONS CONTAINING AROMATIC COMPOUNDS AND TERPENOIDS PRESENT IN ALPINIA GALANGA ASTION DEVELOPMENT A/S (DK) 2002-07-04 US claimed
CN-1303295-A Novel synergistic compositions containing aromatic compounds and terpenoids present in alpinia galanga IDA DEV AS (DK) 2001-07-11 CN claimed
EP-1071440-A1 NOVEL SYNERGISTIC COMPOSITIONS CONTAINING AROMATIC COMPOUNDS AND TERPENOIDS PRESENT IN ALPINIA GALANGA Ida Development A/S (DK) 2001-01-31 EP claimed
WO-1999053935-A1 NOVEL SYNERGISTIC COMPOSITIONS CONTAINING AROMATIC COMPOUNDS AND TERPENOIDS PRESENT IN ALPINIA GALANGA IDA DEVELOPMENT A/S (DK) 1999-10-28 WO claimed
WO-2025075465-A1 NOVEL COMPOUND DERIVED FROM MYRISTICA FRAGRANS, AND ANTICANCER COMPOSITION COMPRISING SAME 한국과학기술연구원 2025-04-10 WO disclosed
WO-2023131362-A1 PHENYLPROPANOID DERIVATIVES USTAV EXPERIMENTALNI BOTANIKY AV ČR, V. V. I. (CZ) 2023-07-13 WO disclosed
WO-2023131362-A1 PHENYLPROPANOID DERIVATIVES USTAV EXPERIMENTALNI BOTANIKY AV ČR, V. V. I. (CZ) 2023-07-13 WO disclosed
WO-2019172013-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOSITION 住友化学株式会社 2019-09-12 WO disclosed
US-10202410-B2 Scaphopetalone analogs and their uses BRIGHAM YOUNG UNIVERSITY (US) 2019-02-12 US disclosed
US-10202410-B2 Scaphopetalone analogs and their uses BRIGHAM YOUNG UNIVERSITY (US) 2019-02-12 US disclosed
US-4948796-A TREATING CEREBO-VASCULARE DISEASES TOYAMA CHEMICAL CO., LTD. (JP) 1990-08-14 US disclosed
EP-0273678-A2 Aromatic derivative and preparation method thereof TEIJIN LIMITED (JP) 1988-07-06 EP disclosed
US-4704462-A PLATELET-ACTIVATING FACTOR MERCK & CO., INC. (US) 1987-11-03 US disclosed
US-4687727-A Light-sensitive planographic printing plate with layer of diazo resin containing photopolymerizable composition FUJI PHOTO FILM CO., LTD. (JP) 1987-08-18 US disclosed
US-4511645-A ALLYL METHACRYLATE-METHACRYLIC ACID COPOLYMER, CURING AGENT, PHOTOINITIATOR FUJI PHOTO FILM CO., LTD. (JP) 1985-04-16 US disclosed
EP-0104863-A2 Light-sensitive planographic printing plate FUJI PHOTO FILM CO., LTD. (JP) 1984-04-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202410-B2 Scaphopetalone analogs and their uses MUSK, SHBG, CYP17A1 CYP1A1 3286/4885PTGS1 2251/4885PTGS2 2622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.